Cipher Pharmaceuticals Future Growth

Future criteria checks 0/6

Cipher Pharmaceuticals's earnings are forecast to decline at 14.6% per annum while its annual revenue is expected to grow at 1.3% per year. EPS is expected to decline by 16.2% per annum. Return on equity is forecast to be 7.3% in 3 years.

Key information

-14.6%

Earnings growth rate

-16.2%

EPS growth rate

Pharmaceuticals earnings growth	74.8%
Revenue growth rate	1.3%
Future return on equity	7.3%
Analyst coverage	Low
Last updated	10 May 2024

Recent future growth updates

Recent updates

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Mar 23

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Mar 22

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

May 14

Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)

May 18

Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next

Mar 20

Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%

Jan 26

Earnings and Revenue Growth Forecasts

TSX:CPH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	21	10	N/A	18	2
12/31/2025	22	12	N/A	18	2
12/31/2024	22	14	N/A	13	3
3/31/2024	22	23	14	14	N/A
12/31/2023	21	20	16	16	N/A
9/30/2023	21	32	15	15	N/A
6/30/2023	20	28	13	13	N/A
3/31/2023	20	27	13	13	N/A
12/31/2022	21	27	11	11	N/A
9/30/2022	22	10	15	15	N/A
6/30/2022	21	8	11	11	N/A
3/31/2022	22	9	11	11	N/A
12/31/2021	22	8	14	14	N/A
9/30/2021	22	5	14	14	N/A
6/30/2021	23	6	12	12	N/A
3/31/2021	21	3	11	11	N/A
12/31/2020	22	4	11	12	N/A
9/30/2020	21	7	7	7	N/A
6/30/2020	22	3	10	11	N/A
3/31/2020	23	4	11	12	N/A
12/31/2019	22	3	7	8	N/A
9/30/2019	23	-1	6	8	N/A
6/30/2019	22	2	4	6	N/A
3/31/2019	23	3	0	2	N/A
12/31/2018	23	1	1	8	N/A
9/30/2018	28	6	7	13	N/A
6/30/2018	34	9	12	18	N/A
3/31/2018	37	11	14	19	N/A
12/31/2017	40	11	N/A	13	N/A
9/30/2017	34	7	N/A	11	N/A
6/30/2017	32	5	N/A	9	N/A
3/31/2017	31	1	N/A	10	N/A
12/31/2016	30	4	N/A	11	N/A
9/30/2016	33	6	N/A	8	N/A
6/30/2016	34	2	N/A	7	N/A
3/31/2016	34	1	N/A	7	N/A
12/31/2015	34	2	N/A	8	N/A
9/30/2015	32	3	N/A	12	N/A
6/30/2015	30	13	N/A	16	N/A
3/31/2015	30	18	N/A	19	N/A
12/31/2014	29	19	N/A	25	N/A
9/30/2014	33	31	N/A	23	N/A
6/30/2014	32	27	N/A	18	N/A
3/31/2014	29	25	N/A	15	N/A
12/31/2013	25	24	N/A	7	N/A
9/30/2013	17	9	N/A	5	N/A
6/30/2013	13	6	N/A	3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CPH's earnings are forecast to decline over the next 3 years (-14.6% per year).

Earnings vs Market: CPH's earnings are forecast to decline over the next 3 years (-14.6% per year).

High Growth Earnings: CPH's earnings are forecast to decline over the next 3 years.

Revenue vs Market: CPH's revenue (1.3% per year) is forecast to grow slower than the Canadian market (7.2% per year).

High Growth Revenue: CPH's revenue (1.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CPH's Return on Equity is forecast to be low in 3 years time (7.3%).

Cipher Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 53%

Consensus EPS estimates increase by 17%

Consensus revenue estimates decrease by 12%

Price target increased to CA$4.13

Price target increased to CA$3.30

Consensus EPS estimates increase to US$0.31

Recent updates

First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Investor sentiment improves as stock rises 27%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 53%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment improves as stock rises 15%

Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Consensus EPS estimates increase by 17%

Consensus revenue estimates decrease by 12%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Interim CEO & Chairman of the Board exercised options to buy CA$411k worth of stock.

Interim CEO & Chairman of the Board exercised options to buy CA$462k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023

Independent Director recently sold CA$61k worth of stock

Price target increased to CA$4.13

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)

Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer

Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022

John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

First quarter 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to CA$3.30

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020)

Investor sentiment improved over the past week

Consensus EPS estimates increase to US$0.31

Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020)

Price target increased to CA$1.82

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$21.5m

Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)

First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020)

Consensus EPS estimates fall to US$0.17

Investor sentiment improved over the past week

Price target increased to CA$1.69

Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next

Cipher Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 18, 2021

Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%

Price target raised to CA$1.65

Cipher Pharmaceuticals Receives Arbitration Award on Trulance

Investor sentiment improved over the past week

New 90-day high: CA$1.15

Third quarter 2020 earnings released: EPS US$0.06

Revenue and earnings beat expectations

New 90-day low: CA$0.93

Cipher Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: CA$1.02

Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as Director

New 90-day low: CA$1.09